Skip to main content

Table 1 Distribution of prognostic factors in different medication groupsa

From: Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study

  Antidiabetic medication Use of statins
Metforminb Other oral ADMb Metformin and other oral ADMb Insulin No use of ADM Yesb No Total
Number of patients 77 58 100 82 104 186 235 421
Age at diagnosis, years
 Median 69 75 70 71 72 71 71 71
 IQRc 63─77 66─80 61─77 65─78 64─79 65─77 62─78 64─78
Age categories, years (%)
 42─59 8 (10) 6 (10) 19 (19) 9 (11) 17 (16) 18 (10) 41 (17) 59 (14)
 60─69 33 (43) 13 (22) 31 (31) 28 (34) 27 (26) 66 (35) 66 (28) 132 (31)
 70─79 30 (39) 24 (41) 42 (42) 29 (35) 35 (34) 74 (40) 86 (37) 160 (38)
 80─92 6 (8) 15 (26) 8 (8) 16 (20) 25 (24) 28 (15) 42 (18) 70 (17)
Duration of T2D, years (%)
 Median 3.1 5.0 6.2 10.8 7.0 6.3 5.7 6.2
 IQRc 2.0─5.5 3.1─8.3 4.1─8.9 6.8─15.0 2.0─10.1 3.1─10.0 3.1─10.0 3.1─10.1
 0.5 ─ < 3 37 (48) 15 (26) 13 (13) 4 (5) 34 (33) 45 (24) 58 (25) 103 (24)
 3 ─ < 6 24 (31) 20 (34) 30 (30) 13 (16) 13 (12) 40 (22) 60 (26) 100 (24)
 6 ─ < 12 14 (18) 19 (33) 44 (44) 30 (37) 41 (39) 71 (38) 77 (33) 148 (35)
 12 ─ < 34 2 (3) 4 (7) 13 (13) 35 (43) 16 (15) 30 (16) 40 (17) 70 (17)
Stage (%)
 Local 14 (18) 6 (10) 11 (11) 11 (13) 10 (10) 24 (13) 28 (12) 52 (12)
 Advanced 58 (75) 45 (78) 77 (77) 64 (78) 86 (83) 142 (76) 188 (80) 330 (78)
 Unknown 5 (6) 7 (12) 12 (12) 7 (9) 8 (8) 20 (11) 19 (8) 39 (9)
  1. aThe entries are number and percentages (in parenthesis) if not otherwise stated
  2. bDuration of medication ≥180 days
  3. cInterquartile range
\